Year-end budget cycles present a strategic opportunity for research teams to invest remaining funds in high-quality biospecimens that will advance studies in the coming year. FFPE tissue samples represent an ideal year-end investment—stable for long-term storage, ready for immediate use in Q1 research programs, and available with the comprehensive clinical annotation necessary for meaningful translational studies.
MT Group specializes in providing access to unusual cancers and disease states that are challenging to source elsewhere. Our dual pathologist-reviewed FFPE blocks come with validated clinical data and rigorous quality control, ensuring your year-end investment delivers reliable research value. Whether you need rare tumor types to fill gaps in existing biobanks, matched tissue sets for multi-omic studies, or treatment-naive specimens for baseline research, MT Group’s curated inventory supports diverse research objectives.
Strategic Value of FFPE for Year-End Investment / Long-Term Research Enablement
FFPE tissue blocks provide exceptional stability at room temperature, enabling multi-year research programs without concerns about specimen degradation. Unlike fresh or frozen biospecimens requiring specialized storage and immediate use, FFPE blocks can be banked and accessed as research priorities evolve. This makes them ideal investments for deploying year-end budgets on specimens that will support ongoing and future studies rather than requiring immediate consumption.
Comprehensive Clinical Annotation Maximizes Value
Every MT Group FFPE block includes detailed clinical documentation—patient demographics, disease diagnosis and staging, treatment history, biomarker status when available, and surgical pathology reports. This comprehensive annotation transforms tissue blocks from simple specimens into research-ready resources that provide clinical context for interpreting findings. Well-annotated FFPE samples support multiple downstream applications including immunohistochemistry, spatial profiling, genomic analyses, and biomarker validation studies.
Access to Unusual Cancers Fills Critical Gaps
MT Group’s repository includes challenging-to-source specimens such as cholangiocarcinoma, glioblastoma, pancreatic adenocarcinoma, hepatocellular carcinoma, and NASH liver biopsies. These rare FFPE samples enable research programs that would otherwise face lengthy prospective collection timelines, allowing teams to begin studies immediately rather than waiting months for specimen procurement.
Matched Sets Enable Multi-Omic Approaches
Matched FFPE-plasma-buffy coat cases from the same patients enable powerful multi-omic research strategies. Tissue-based findings can be correlated with circulating biomarkers, supporting liquid biopsy development, concordance studies, and comprehensive molecular profiling across sample types. These matched biospecimen sets maximize research value by providing multiple specimen formats from individual patients with unified clinical annotation.
MT Group’s Quality Advantage
Dual Pathologist Review
Every FFPE tissue block undergoes review by a pathologist at the collection site prior to release, followed by independent confirmation by MT Group’s two board-certified pathologists. This multi-level review process verifies diagnostic accuracy, confirms adequate tumor content and tissue quality, and ensures specimens meet precise disease criteria required for research. Dual pathologist review provides confidence that FFPE blocks are correctly diagnosed and suitable for downstream applications, reducing risk of misclassified specimens compromising research outcomes.
Clinical Data Validation
MT Group’s dedicated clinical data team meticulously reviews all clinical documentation for completeness and internal consistency before specimens are released. This rigorous validation ensures accurate disease staging, complete treatment histories, and reliable clinical annotation that maximizes research value. Comprehensive annotation is as critical as tissue quality for successful translational research.
Tumor Content Verification
All FFPE blocks are verified to contain a minimum of 40% tumor content, with most specimens significantly exceeding this threshold—often 60-80% tumor cellularity. Pathology reports documenting tumor content percentage accompany each specimen, enabling researchers to select blocks that meet specific study requirements. This tumor content guarantee ensures sufficient malignant cells for successful downstream analyses without wasting valuable samples on inadequate specimens.
Specimen Replacement Guarantee
MT Group stands behind the quality of every FFPE tissue block delivered. If any specimen fails to meet agreed-upon specifications such as tumor content percentage, tissue quality, diagnostic accuracy, or processing parameters, we replace the specimen at no additional cost. This guarantee protects research investments and ensures FFPE blocks arrive ready for immediate use in critical experiments.
Available Inventory Highlights
MT Group maintains curated FFPE inventory with particular depth in challenging-to-source specimens:
Rare Tumor Types:
Cholangiocarcinoma (bile duct cancer), glioblastoma (GBM), pancreatic adenocarcinoma, and hepatocellular carcinoma (HCC) represent some of the most difficult cancers to source due to low incidence rates, poor prognosis limiting tissue availability, or anatomic location challenges. MT Group’s access to these rare specimens enables research programs that cannot rely on standard biobank inventory.
High-Demand Disease States:
NASH (non-alcoholic steatohepatitis) liver biopsies, Crohn’s disease tissue, and ulcerative colitis specimens support growing research areas in metabolic disease and inflammatory bowel disease where tissue access remains limited. These disease states are increasingly important for therapeutic development but challenging to source with appropriate clinical characterization.
Targeted Cancer Subtypes:
Triple-negative breast cancer (TNBC) and gastroesophageal junction (GEJ) tumors represent molecularly or anatomically distinct disease entities requiring specialized specimens. TNBC lacks hormone receptor and HER2 expression, making it a critical subtype for immunotherapy and targeted therapy research. GEJ tumors occupy a unique anatomic position with distinct biology from pure gastric or esophageal cancers.
Treatment-Naive Specimens:
FFPE blocks from patients who have not received prior systemic therapy provide baseline disease biology unconfounded by therapeutic effects. Treatment-naive specimens are valuable for understanding intrinsic tumor characteristics, establishing pre-treatment biomarker profiles, and studying disease in its natural state before therapeutic intervention.
Early-Stage Disease:
Early-stage specimens from common cancers (breast, lung, colorectal, ovarian) are less readily available than advanced-stage disease, as early cancers are often cured rather than progressing to research-accessible timepoints. Early-stage FFPE blocks enable studies of disease initiation, early biomarker development, and biology distinct from metastatic disease.
Matched FFPE-Plasma-Buffy Coat Sets:
Matched biospecimen sets with FFPE tumor tissue paired with plasma and buffy coat from the same patients enable concordance studies, biomarker validation across matrices, and multi-omic research approaches. These matched sets are particularly valuable for liquid biopsy development and understanding relationships between tissue and circulating biomarkers.
Frequently Asked Questions
What lead time should we expect for FFPE block delivery?
FFPE blocks from MT Group’s onsite repository typically require 1-2 weeks for delivery after specimen selection and order placement. Blocks accessed from collection sites within our virtual biobank network require somewhat longer timelines for transfer to MT Group and quality control. Delivery timelines include pathologist review confirmation for selected blocks, clinical data validation and preparation of accompanying documentation, and shipment logistics. MT Group’s business development team provides specific timelines for each project based on specimen availability and quality control status.
Can you invoice in current year and fulfill orders in the new year?
Yes, MT Group can accommodate year-end budget deployment by invoicing specimens in the current fiscal year with delivery scheduled for early in the following year. This arrangement allows research teams to utilize remaining budget allocations while aligning specimen delivery with Q1 research timelines. We work with finance teams to structure invoicing and delivery schedules that meet both budgetary requirements and research program needs. Contact us to discuss specific timing requirements for your year-end procurement.
What is your quality review process for FFPE blocks?
MT Group’s quality review process includes multiple verification steps: pathologist review at the collection site confirms initial diagnosis and tissue adequacy; MT Group’s two board-certified pathologists independently review and confirm diagnosis, tumor content, and tissue quality; our clinical data team validates all accompanying clinical documentation for completeness and accuracy; and final quality control verifies that specimens meet agreed-upon specifications before release. This multi-level review ensures only high-quality, correctly characterized FFPE blocks are delivered to researchers.
Do you have matched FFPE-plasma-buffy coat cases in your bank?
Yes, MT Group maintains inventory of matched biospecimen sets with FFPE tumor tissue paired with plasma and buffy coat from the same patients. These matched sets enable concordance studies between tissue-based and liquid biopsy assays, biomarker validation across sample matrices, and multi-omic research approaches. Availability of matched sets varies by tumor type—contact us for current inventory of specific cancers with matched biofluids. Matched sets represent particularly high value for year-end investment as they support multiple research applications from single patient cohorts.
Can I request specific inventory before committing?
Yes, MT Group provides customized inventory output sheets based on your specific requirements. Request an output sheet by contacting us with details including disease state, stage, treatment history (treatment-naive vs. treated), minimum tumor content percentage, desired clinical data elements, and quantity needed. We generate a specimen list with available cases matching your criteria, including summary clinical information for each specimen. You can review the output sheet, select specific cases of interest, and we provide detailed case report forms for chosen specimens before finalizing your order. This selection process ensures FFPE blocks precisely match your research objectives before budget commitment.
Email Us
"*" indicates required fields
